查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999328

先进治疗药物（ATMP）CDMO市场：按产品类型、服务类型、治疗领域、应用和最终用户分類的全球市场预测，2026-2032年

Advanced Therapy Medicinal Products CDMO Market by Product Type, Service Type, Therapeutic Area, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，先进药品 (ATMP) 的 CDMO 市值将达到 89.7 亿美元，到 2026 年将成长到 104.3 亿美元，到 2032 年将达到 284.6 亿美元，复合年增长率为 17.92%。

主要市场统计数据
基准年 2025 89.7亿美元
预计年份：2026年 104.3亿美元
预测年份 2032 284.6亿美元
复合年增长率 (%) 17.92%

简明策略框架阐述了技术成熟度和营运需求如何重塑 CDMO 在细胞、基因和组织工程治疗中的作用。

先进治疗药物（ATMP）的合约开发与生产（CDMO）产业处于科学创新与工业规模生物製程的交汇点。细胞疗法、基因疗法和组织工程的快速发展正在改变服务供应商的开发路径和营运预期，这要求其在分析、製程开发、生产和法规遵从等各个方面进行能力重组。随着申办者从探索性研究转向临床和商业化供应，对能够将深厚的生物工艺专业知识与法规策略、品质系统和可扩展的生产平台相结合的合作伙伴的需求日益增长。

科学创新、监管预期和商业化压力如何迫使CDMO扩大自身能力并建立更深的伙伴关係。

ATMP（先进治疗药物）领域的变革性变化源自于科学突破与商业性预期的融合，迫使CDMO（合约研发生产机构）超越传统的生产服务模式。载体设计、细胞工程和支架技术的进步增加了製程的复杂性，同时也为实现以往无法达到的持续临床疗效开闢了道路。因此，CDMO必须平衡对细胞和载体分析的投资（以实现可靠的表征和可比性）与对专用无尘室设施和一次性使用技术的投资。

为因应 2025 年关税带来的供应链和製造地策略调整，以维持连续性和成本效益。

将于2025年实施的新关税措施增加了成本和复杂性，相关人员在采购原材料、专用一次性组件和跨境製造服务时必须应对这些因素。关税带来的成本压力促使赞助商和服务供应商重新评估供应链韧性，实现供应商多元化，并尽可能加快在地化策略。在某些情况下，製造商正在重新考虑其采购计划，优先选择来源透明且关税合规记录良好的供应商，以减少海关延误和意外成本增加。

详细的基于细分的分析表明，产品形式、服务范围、治疗领域、临床阶段和最终用户概况如何定义差异化的 CDMO 价值提案。

细分市场洞察揭示了不同的需求驱动因素和能力要求，这些因素应指南产品组合开发和市场策略。根据产品类型，该领域包括细胞治疗产品、基因治疗产品和组织工程产品。在细胞治疗领域，需求分为非干细胞疗法和干细胞疗法；在基因治疗领域，需求又分为细胞株疗法和体细胞基因疗法。每种疗法都有其独特的生产和监管方面的考量。这些模式差异会影响供应商必须提供的分析类型和规模、疗效检测以及出货测试，以降低临床开发中的风险。

区域製造生态系统和监管条件如何影响先进治疗药物的供应商选择和生产能力的地理分布

区域趋势正在重塑赞助商进行研发和确保商业性供应的地点，地理优势和限制影响着供应商的专业化方向和客户合作模式。在美洲，对灵活製造和先进分析的投资正在打造一个支持规模化生产的中心，强调早期计画快速过渡到临床试验。人才集中和完善的监管管道使该地区对复杂治疗方法的研发极具吸引力，但高昂的营运成本促使混合模式的出现，即将国内生产能力与非核心流程的海外生产相结合。

对供应商策略的评估表明，能力整合、有针对性的专业化和策略伙伴关係正在塑造 CDMO 服务的竞争优势。

在企业层面，发展趋势聚焦于能力整合、平台扩充性以及连结科学研发和商业化准备的策略伙伴关係。主要企业正投资建构端到端的能力体系，将严谨的分析测试、先进的製程开发和监管支援相结合，为复杂的细胞和基因治疗项目提供一致的价值提案。这些投资通常与有针对性的合作伙伴关係、技术授权或共同开发契约相结合，从而加速获取专用载体、细胞增殖平台和疗效评估技术。

为先进治疗性CDMO各领域的领导者提供切实可行的策略，以增强韧性、扩展能力并建立更深入、风险共用的伙伴关係。

产业领导者应采取前瞻性策略，兼顾短期业务永续营运和长期能力建构。当务之急包括：提高关键原材料和一次性耗材的供应链透明度；正式製定多通路采购策略以降低关税和物流风险；以及实施符合多个司法管辖区监管要求的健全库存管理和批次追踪机制。同时，增加对先进分析技术和功效测试的投资，将有助于提高批次放行的可比性和可信度，并减少下游监管方面的阻力。

我们采用严谨的混合方法研究途径，结合一手访谈、技术文献综述和能力映射，为决策者提供检验的见解。

本报告的分析整合了第一手和第二手资料，旨在提供基于实证的洞察，深入剖析医疗服务提供者的能力、市场动态和营运趋势。第一手资料包括对处于研发阶段的赞助公司的高级领导、生产主管、製程科学家和监管专家的结构化访谈，从而获取关于营运重点和伙伴关係标准的第一手观点。二级资讯来源包括同行评审文献、监管指导文件和技术白皮书，对与先进治疗方法相关的技术和合规趋势进行了多角度的检验。

策略挑战在于如何协调科学平台、製造系统和监管远见，以支持先进治疗计画的整个生命週期。

在先进治疗方法领域，CDMO（合约研发生产机构）的策略日益注重建立稳固的伙伴关係卓越的科学研究实力、严谨的生产製造和前瞻性的监管策略相结合，以降低专案风险并加速患者获得治疗。日益复杂的技术、不断变化的关税趋势以及区域生产环境等多重压力，使得申办方和供应商都必须采用灵活的、基于平台的模式，并深化从基础研究到规模化生产的合作。将分析、模组化设施和合规基础设施的投资与目标治疗领域的专业知识相结合，能够帮助相关人员在整个研发阶段提高可预测性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 先进治疗药物（ATMP）CDMO市场：依产品类型划分

  • 细胞治疗产品
    • 非干细胞疗法
    • 干细胞疗法
  • 基因治疗产品
    • 生殖细胞疗法
    • 体细胞基因治疗
  • 组织工程产品

第九章 先进治疗药物（ATMP）CDMO市场：依服务类型划分

  • 分析测试和品管
  • 製造服务
  • 流程开发服务
  • 监管和合规支持

第十章 先进治疗药物（ATMP）CDMO市场：依治疗领域划分

  • 循环系统
  • 皮肤科
  • 血液学
  • 神经病学
  • 肿瘤学

第十一章 先进治疗药物（ATMP）CDMO市场：依应用领域划分

  • 临床阶段
  • 商业阶段

第十二章 先进治疗药物（ATMP）CDMO市场：依最终用户划分

  • 学术和研究机构
  • 生物製药公司

第十三章 先进治疗药物（ATMP）CDMO市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 先进治疗药物（ATMP）CDMO市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 先进治疗药物（ATMP）CDMO市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国先进治疗药物（ATMP）CDMO市场

第十七章：中国先进治疗药物（ATMP）CDMO市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abzena
  • Advanced Therapies, LLC
  • AGC Inc.
  • Aldevron
  • Almac Group
  • Bio Elpida by Polyplus
  • BlueReg
  • Catalent Inc.
  • CELONIC Group
  • CGT Catapult
  • Charles River Laboratories International, Inc.
  • Coriolis Pharma Research GmbH
  • Curia Global, Inc.
  • Eurofins Scientific SE
  • FUJIFILM Diosynth Biotechnologies
  • Lonza Group
  • Minaris Regenerative Medicine
  • Oxford Biomedica PLC
  • Patheon by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Rentschler Biopharma SE
  • REPROCELL Inc.
  • RoslinCT
  • Samsung Biologics
  • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market was valued at USD 8.97 billion in 2025 and is projected to grow to USD 10.43 billion in 2026, with a CAGR of 17.92%, reaching USD 28.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.97 billion
Estimated Year [2026] USD 10.43 billion
Forecast Year [2032] USD 28.46 billion
CAGR (%) 17.92%

A concise strategic framing of how technological maturation and operational demands are reshaping CDMO roles for cell, gene, and tissue engineered therapeutics

The advanced therapy medicinal products (ATMP) contract development and manufacturing organization (CDMO) sector sits at the intersection of scientific innovation and industrial-scale bioprocessing. Rapid advances in cell therapy, gene therapy, and tissue engineering are shifting development pathways and operational expectations for service providers, triggering a reframing of capabilities across analytical, process development, manufacturing, and regulatory functions. As sponsors progress from exploratory research to clinical and commercial supply, they increasingly require partners who can integrate deep bioprocess expertise with regulatory strategy, quality systems, and scalable manufacturing platforms.

This executive summary synthesizes current dynamics shaping provider selection, investment priorities, and competitive differentiation. It emphasizes how technological maturation, regulatory evolution, and supply chain realities are driving CDMOs to expand service breadth while enhancing specialization. The narrative connects scientific trends to operational imperatives, offering leaders a clear perspective on where to align resources, which capability gaps to prioritize closing, and how to position organizations to support both small molecule-free biologics and complex engineered modalities. The intent is to help decision-makers convert technical insights into practical strategic actions that reduce program risk and accelerate timelines without compromising quality or compliance.

How converging scientific innovation, regulatory expectations, and commercialization pressures are compelling CDMOs to expand capabilities and form deeper partnerships

Transformative shifts in the ATMP landscape are driven by the confluence of scientific breakthroughs and commercial expectations, pressing CDMOs to evolve beyond traditional manufacturing service models. Advances in vector design, cell engineering, and scaffold technologies are increasing process complexity while simultaneously opening routes to durable clinical responses that were previously unattainable. As a result, CDMOs must balance investments in specialized cleanroom architectures and single-use technologies with investments in cell and vector analytics that enable robust characterization and comparability.

Concurrently, payers and regulators are emphasizing long-term evidence generation and supply consistency, which motivates sponsors to select partners capable of supporting lifecycle strategies from early clinical development through commercialization. This dynamic is fostering deeper strategic alliances where CDMOs participate in platform development, regulatory filing support, and post-market manufacturing assurance. The shift places a premium on flexible capacity, data integrity, and cross-functional project governance, with successful providers demonstrating an ability to de-risk development pathways while optimizing cost and time to clinic.

Navigating the 2025 tariff-driven recalibration of supply chains and manufacturing location strategies to maintain continuity and cost-effectiveness

The imposition of new tariff measures in 2025 has introduced an additional cost and complexity vector that stakeholders must navigate in sourcing raw materials, specialized single-use components, and cross-border manufacturing services. Tariff-driven cost pressures have prompted sponsors and service providers to reassess supply chain resilience, diversifying supplier bases and accelerating localization strategies where feasible. In some cases, manufacturers are reconfiguring procurement plans to prioritize vendors with transparent origin and tariff compliance histories to reduce customs delays and unexpected cost pass-throughs.

Moreover, the tariff environment has influenced strategic decisions around where to locate manufacturing capacity for clinical and commercial supply. Sponsors are increasingly weighing the trade-offs between centralized high-capacity sites versus distributed regional manufacturing models that can mitigate tariff exposure and shorten logistical pathways. Regulatory dossiers and quality systems must be adjusted to reflect multi-jurisdictional production plans, and CDMOs are responding by enhancing customs expertise, implementing robust inventory buffers, and developing cost-allocation frameworks that preserve program economics while maintaining supply reliability.

A nuanced segmentation-driven lens showing how product modalities, service scopes, therapeutic areas, application stages, and end-user profiles define differentiated CDMO value propositions

Segmentation insights reveal differentiated demand drivers and capability requirements that should guide portfolio development and go-to-market strategies. Based on Product Type, the landscape includes Cell Therapy Products, Gene Therapy Products, and Tissue Engineered Products; within cell therapies, demand separates between Non-stem Cell Therapy and Stem Cell Therapy, while gene therapy distinctions arise between Germline Therapy and Somatic Gene Therapy, each pathway carrying unique manufacturing and regulatory considerations. These modality distinctions influence the type and scale of analytics, potency assays, and release testing that providers must offer to de-risk clinical progression.

Based on Service Type, service expectations encompass Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, and Regulatory & Compliance Support, and the most competitive providers integrate these capabilities to provide seamless technology transfer and comparability assessments. Based on Therapeutic Area, the sector spans Cardiology, Dermatology, Hematology, Neurology, and Oncology, with oncology and hematology programs frequently demanding accelerated timelines, complex release criteria, and higher regulatory scrutiny. Based on Application, differentiation between Clinical Stage and Commercial Stage use cases requires flexibility in batch size, facility qualification, and supply chain robustness. Based on End-User, the market engages both Academic & Research Institutes and Biopharmaceutical Companies, which present divergent needs around cost sensitivity, regulatory sophistication, and expectations for long-term manufacturing partnerships.

Taken together, these segmentation axes show that successful service providers must architect modular offerings that can be configured to meet modality-specific analytical demands, therapeutic area nuances, and the distinct operational rhythms of early-stage researchers versus commercial sponsors. This segmentation-informed approach enables targeted investment in platform technologies and quality infrastructures that align with customer priorities and regulatory pathways.

How regional manufacturing ecosystems and regulatory landscapes are influencing sourcing choices and the geographical distribution of advanced therapy production capacity

Regional dynamics are reshaping where sponsors elect to conduct development and secure commercial supply, with geographic strengths and constraints influencing provider specialization and client engagement models. In the Americas, investment into flexible manufacturing and advanced analytics is creating hubs that emphasize speed to clinic for early-phase programs and support for scale-up activities. Talent concentration and established regulatory pathways make the region attractive for complex modality development, but high operational costs incentivize hybrid models that combine domestic capacity with offshore manufacturing for non-core processes.

In Europe, Middle East & Africa, regulatory harmonization efforts and incentives in several jurisdictions support a diverse provider ecosystem that blends academic spinouts with industrial-scale CDMOs. This regional tapestry fosters collaborative innovation but also requires close attention to cross-border regulatory alignment and localized compliance requirements. In Asia-Pacific, rapid capacity expansion, competitive manufacturing cost structures, and growing scientific talent pools are driving an increasing share of clinical and commercial manufacturing activities, though sponsors must carefully evaluate quality standards and supply chain traceability when engaging new partners.

These regional distinctions encourage sponsors to adopt multi-regional sourcing strategies that balance speed, cost, and regulatory security. Providers that can demonstrate validated processes across jurisdictions, harmonized quality systems, and robust logistics will be better positioned to capture cross-border demand and to support clients pursuing global clinical development and commercialization pathways.

An assessment of provider strategies showing how capability consolidation, targeted specialization, and strategic partnerships are shaping competitive advantage in CDMO services

Company-level dynamics are centered on capability integration, platform scalability, and strategic partnerships that bridge scientific development with commercial readiness. Leading providers are investing in end-to-end capability stacks, combining rigorous analytical testing, advanced process development, and regulatory support to present cohesive value propositions for complex cell and gene therapy programs. These investments often pair with targeted alliances, technology licenses, or joint development agreements that accelerate access to specialized vectors, cell expansion platforms, and potency assay technologies.

At the same time, the competitive field includes specialist providers that maintain high-value niches, such as vector manufacturing or bespoke tissue engineering services, which can be highly attractive to sponsors seeking domain-specific expertise. Mergers and acquisitions continue to be a strategic lever for scaling capacity and absorbing specialized know-how, while organic investments in single-use infrastructure and digital quality systems enhance operational responsiveness. For sponsors, the optimal partner selection balances an assessment of technical fit, track record in regulatory submissions, and the provider's governance model for risk sharing and traceability during technology transfers.

Actionable strategies for leaders to enhance resilience, scale capabilities, and forge deeper, risk-aligned partnerships across the advanced therapy CDMO continuum

Industry leaders should adopt a proactive agenda that balances near-term operational resilience with longer-term capability building. Immediate priorities include strengthening supply chain transparency for critical raw materials and single-use consumables, formalizing multi-sourcing strategies to mitigate tariff and logistics exposure, and implementing robust inventory and batch-tracking mechanisms that align with multi-jurisdictional regulatory expectations. Parallel investments in advanced analytics and potency assays will improve comparability and batch release confidence, reducing downstream regulatory friction.

Over the medium term, organizations should prioritize modular facility design and platform standardization to enable rapid scaling from clinical to commercial manufacture. Cultivating strategic partnerships with vector specialists, academic translation centers, and technology licensors can accelerate time-to-clinic while distributing development risk. Leadership should also invest in workforce development programs that build cross-disciplinary expertise in process development, regulatory affairs, and quality systems. Finally, aligning commercial engagement models to offer outcome-linked milestones or shared risk arrangements can differentiate providers and foster deeper, longer-term sponsor relationships that support streamlined development and market entry.

A rigorous mixed-method research approach integrating primary interviews, technical literature review, and capability mapping to deliver validated insights for decision-makers

The analysis underpinning this report synthesizes primary and secondary inputs to produce an evidence-based view of provider capabilities, market dynamics, and operational trends. Primary research included structured interviews with senior leaders across development-stage sponsors, manufacturing executives, process scientists, and regulatory specialists to capture first-hand perspectives on operational priorities and partnership criteria. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and technical white papers to triangulate technological and compliance trends relevant to advanced modalities.

Analytical methods combined qualitative thematic analysis of interview transcripts with capability mapping and scenario-based risk assessment to evaluate how tariff changes, regional dynamics, and modality complexity influence sourcing and manufacturing strategies. Comparative provider profiling emphasized observable metrics such as facility type, service breadth, historical regulatory interactions, and documented platform technologies. Where possible, the methodology prioritized verifiable, primary-source evidence and cross-validation to ensure findings are robust and actionable for decision-makers seeking to align manufacturing strategies with clinical and commercial objectives.

Strategic imperatives for aligning scientific platforms, manufacturing readiness, and regulatory foresight to support the full lifecycle of advanced therapy programs

Advanced therapy CDMO strategy is increasingly about orchestrating scientific excellence, manufacturing rigor, and regulatory foresight into cohesive partnerships that reduce program risk and accelerate patient access. The combined pressures of technological complexity, tariff dynamics, and regional manufacturing evolution make it imperative for both sponsors and providers to adopt flexible, platform-based approaches and to deepen collaborations that bridge bench science to scalable production. By aligning investments in analytics, modular facilities, and compliance infrastructure with targeted therapeutic area expertise, stakeholders can improve predictability across development stages.

Decision-makers who prioritize transparent supply chains, validated multi-regional capabilities, and shared-risk commercial models will be better positioned to navigate uncertainty while capturing the value of advanced modalities. The path forward is one of selective specialization complemented by interoperable platforms, enabling providers to support the full lifecycle of ATMP programs while maintaining quality and regulatory alignment. This strategic orientation will determine which organizations can reliably serve the complex needs of next-generation therapeutics and sustain long-term partnerships with sponsors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Therapy Medicinal Products CDMO Market, by Product Type

  • 8.1. Cell Therapy Products
    • 8.1.1. Non-stem Cell Therapy
    • 8.1.2. Stem Cell Therapy
  • 8.2. Gene Therapy Products
    • 8.2.1. Germline Therapy
    • 8.2.2. Somatic Gene Therapy
  • 8.3. Tissue Engineered Products

9. Advanced Therapy Medicinal Products CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing Services
  • 9.3. Process Development Services
  • 9.4. Regulatory & Compliance Support

10. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Hematology
  • 10.4. Neurology
  • 10.5. Oncology

11. Advanced Therapy Medicinal Products CDMO Market, by Application

  • 11.1. Clinical Stage
  • 11.2. Commercial Stage

12. Advanced Therapy Medicinal Products CDMO Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies

13. Advanced Therapy Medicinal Products CDMO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Therapy Medicinal Products CDMO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Therapy Medicinal Products CDMO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Advanced Therapy Medicinal Products CDMO Market

17. China Advanced Therapy Medicinal Products CDMO Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abzena
  • 18.6. Advanced Therapies, LLC
  • 18.7. AGC Inc.
  • 18.8. Aldevron
  • 18.9. Almac Group
  • 18.10. Bio Elpida by Polyplus
  • 18.11. BlueReg
  • 18.12. Catalent Inc.
  • 18.13. CELONIC Group
  • 18.14. CGT Catapult
  • 18.15. Charles River Laboratories International, Inc.
  • 18.16. Coriolis Pharma Research GmbH
  • 18.17. Curia Global, Inc.
  • 18.18. Eurofins Scientific SE
  • 18.19. FUJIFILM Diosynth Biotechnologies
  • 18.20. Lonza Group
  • 18.21. Minaris Regenerative Medicine
  • 18.22. Oxford Biomedica PLC
  • 18.23. Patheon by Thermo Fisher Scientific Inc.
  • 18.24. Recipharm AB
  • 18.25. Rentschler Biopharma SE
  • 18.26. REPROCELL Inc.
  • 18.27. RoslinCT
  • 18.28. Samsung Biologics
  • 18.29. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)